Related Experiment Video
Updated: Mar 19, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Effect of Post-Primary Percutaneous Coronary Intervention Bivalirudin Infusion on Acute Stent Thrombosis:
Rahman Shah1, Kelly C Rogers2, Agha J Ahmed3
1Section of Cardiology, University of Tennessee, School of Medicine, Memphis, Tennessee; Veterans Affairs Medical Center, Memphis, Tennessee.
Insights
Continuing full-dose bivalirudin infusion after percutaneous coronary intervention (PCI) may mitigate the increased risk of acute stent thrombosis (AST) associated with its use. This strategy also preserves the significant reduction in major bleeding risk compared to heparin.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Bivalirudin infusion post-PCI is used to reduce acute stent thrombosis (AST).
- Recent trials using full (Biv-Full) or low (Biv-Low) doses showed varied results.
- A meta-analysis was conducted to determine if AST risk is dose-dependent.
Purpose of the Study:
- To evaluate the efficacy of different doses of post-PCI bivalirudin infusion in preventing AST.
- To compare the dose-dependent risk of AST with bivalirudin versus heparin.
- To assess the impact of bivalirudin dosing on major bleeding risk.
Main Methods:
- A meta-analysis of randomized controlled trials (RCTs) was performed.
- Data from 5 trials involving 16,294 patients were analyzed.
- Network meta-analysis using mixed-treatment comparison models was employed.
Main Results:
- Bivalirudin increased AST risk twofold compared to heparin, but continuing Biv-Full post-PCI ameliorated this risk (RR: 0.90).
- Biv-Low did not show a similar protective effect against AST.
- Bivalirudin significantly decreased major bleeding risk by 47% compared to heparin, a benefit sustained with Biv-Full post-PCI.
Conclusions:
- Continuing Biv-Full (not Biv-Low) for 3-4 hours post-PCI may mitigate the increased AST risk associated with bivalirudin.
- The reduced bleeding risk with bivalirudin is maintained when using the Biv-Full strategy.
Objectives:
The aim of this study was to evaluate the efficacy of various doses of post-primary percutaneous coronary intervention (PCI) bivalirudin infusion to prevent acute stent thrombosis (AST).
Background:
In several recent randomized controlled trials, bivalirudin infusion was continued post-PCI as either a full PCI dose (Biv-Full) or a reduced dose (Biv-Low) to reduce the risk for AST. The results of these trials varied, so the authors performed a meta-analysis of RCTs to determine whether the risk for AST is dose dependent.
Methods:
Scientific databases and Web sites were searched for RCTs. A traditional meta-analysis was performed using moderator analyses and network meta-analysis using mixed-treatment comparison models to compare the efficacy of various bivalirudin doses in reducing AST.
Results:
Data from 5 trials including 16,294 patients were analyzed. Compared with heparin, bivalirudin increased AST risk 2-fold, but this was ameliorated by continuing Biv-Full (risk ratio: 0.90, 95% confidence interval: 0.32 to 2.54; p = 0.852). This effect was not seen with Biv-Low. Similarly, in mixed-treatment models, no difference in AST rate was found between heparin and Biv-Full (odds ratio: 0.97; 95% confidence interval: 0.36 to 2.21). After 30 days, bivalirudin decreased the risk for major bleeding by 47% compared with heparin; this benefit persisted even with continued Biv-Full post-PCI (risk ratio: 0.29; 95% confidence interval: 0.16 to 0.53; p < 0.001).
Conclusions:
Although bivalirudin is associated with a greater risk for AST than heparin post-primary PCI, this limitation may be mitigated by continuing Biv-Full (not Biv-Low) 3 to 4 h post-operatively. The decrease in bleeding risk with bivalirudin compared with heparin is not compromised by this strategy.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:27Coronary Artery Disease V: Interprofessional Care